• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

相似文献

1
Inhibition of KIT Tyrosine Kinase Activity: Two Decades After the First Approval.KIT酪氨酸激酶活性抑制：首次获批二十年后
J Clin Oncol. 2021 May 20;39(15):1674-1686. doi: 10.1200/JCO.20.03245. Epub 2021 Apr 2.
2
The direct association of the multiple PDZ domain containing proteins (MUPP-1) with the human c-Kit C-terminus is regulated by tyrosine kinase activity.含有多个PDZ结构域的蛋白质（MUPP-1）与人类c-Kit C末端的直接关联受酪氨酸激酶活性调控。
FEBS Lett. 2000 Sep 29;482(1-2):54-8. doi: 10.1016/s0014-5793(00)02036-6.
3
JAK2 is associated with the c-kit proto-oncogene product and is phosphorylated in response to stem cell factor.JAK2与c-kit原癌基因产物相关，并在干细胞因子的作用下发生磷酸化。
Blood. 1996 May 1;87(9):3688-93.
4
The reproductive activity in the testis of Podarcis s. sicula involves D-aspartic acid: a study on c-kit receptor protein, tyrosine kinase activity and PCNA protein during annual sexual cycle.意大利壁蜥睾丸中的生殖活动涉及D-天冬氨酸：年度性周期中c-kit受体蛋白、酪氨酸激酶活性和增殖细胞核抗原蛋白的研究
Gen Comp Endocrinol. 2009 May;161(3):373-83. doi: 10.1016/j.ygcen.2009.02.002. Epub 2009 Feb 12.
5
The desmoid tumor: still an enigma.硬纤维瘤：仍是一个谜。
J Surg Res. 2012 Mar;173(1):46-8. doi: 10.1016/j.jss.2011.01.039. Epub 2011 Feb 20.
6
Significance of tyrosine kinases in cancer: overview.酪氨酸激酶在癌症中的意义：概述
Eur J Cancer. 2002 Sep;38 Suppl 5:S2. doi: 10.1016/s0959-8049(02)80596-2.
7
Signaling by Kit protein-tyrosine kinase--the stem cell factor receptor.Kit蛋白酪氨酸激酶（干细胞因子受体）介导的信号传导
Biochem Biophys Res Commun. 2005 Nov 11;337(1):1-13. doi: 10.1016/j.bbrc.2005.08.055.
8
Expression of protein tyrosine kinases in head and neck squamous cell carcinomas.蛋白酪氨酸激酶在头颈部鳞状细胞癌中的表达
Am J Clin Pathol. 2006 Oct;126(4):618.
9
Modulation of Kit/stem cell factor receptor-induced signaling by protein kinase C.蛋白激酶C对Kit/干细胞因子受体诱导信号传导的调节
J Biol Chem. 1994 Aug 26;269(34):21793-802.
10
Inhibition of c-kit receptor tyrosine kinase activity by STI 571, a selective tyrosine kinase inhibitor.选择性酪氨酸激酶抑制剂STI 571对c-kit受体酪氨酸激酶活性的抑制作用。
Blood. 2000 Aug 1;96(3):925-32.

引用本文的文献

1
Molecular genetics profiling of core-binding factor acute myeloid leukemia in pediatrics.儿童核心结合因子急性髓系白血病的分子遗传学分析
Ther Adv Hematol. 2025 Apr 16;16:20406207251330064. doi: 10.1177/20406207251330064. eCollection 2025.
2
[The efficacy and safety of avapritinib in the treatment of molecular biologically positive core binding factor-acute myeloid leukemia with KIT mutation after allogeneic hematopoietic stem cell transplantation].阿伐替尼治疗异基因造血干细胞移植后分子生物学阳性且伴有KIT突变的核心结合因子急性髓系白血病的疗效与安全性
Zhonghua Xue Ye Xue Za Zhi. 2024 Aug 14;45(8):761-766. doi: 10.3760/cma.j.cn121090-20240129-00043.
3
Levels of circulating tumor DNA correlate with tumor volume in gastro-intestinal stromal tumors: an exploratory long-term follow-up study.循环肿瘤 DNA 水平与胃肠间质瘤肿瘤体积相关：一项探索性的长期随访研究。
Mol Oncol. 2024 Nov;18(11):2658-2667. doi: 10.1002/1878-0261.13644. Epub 2024 May 24.
4
If it's a target, it's a pan-cancer target: Tissue is not the issue.如果是靶点，那就是泛癌靶点：组织不是问题。
Cancer Treat Rev. 2024 Apr;125:102721. doi: 10.1016/j.ctrv.2024.102721. Epub 2024 Mar 21.
5
Individualized Dosing Patterns in the Treatment of Older Patients with Gastrointestinal Stromal Tumors: Results of a Registry-Based Observational National Cohort Study Including 871 Patients.个体化剂量模式在老年胃肠道间质瘤患者治疗中的应用：一项基于登记的观察性全国队列研究结果，纳入 871 例患者。
Drugs Aging. 2024 Feb;41(2):165-176. doi: 10.1007/s40266-023-01084-8. Epub 2023 Dec 20.
6
c-Kit Receptors as a Therapeutic Target in Cancer: Current Insights.c-Kit受体作为癌症治疗靶点的当前见解
Onco Targets Ther. 2023 Sep 27;16:785-799. doi: 10.2147/OTT.S404648. eCollection 2023.
7
Mutated KIT Tyrosine Kinase as a Novel Molecular Target in Acute Myeloid Leukemia.急性髓系白血病中突变型 KIT 酪氨酸激酶作为一个新的分子靶点。
Int J Mol Sci. 2022 Apr 23;23(9):4694. doi: 10.3390/ijms23094694.
8
New treatment strategies for advanced-stage gastrointestinal stromal tumours.晚期胃肠道间质瘤的新治疗策略。
Nat Rev Clin Oncol. 2022 May;19(5):328-341. doi: 10.1038/s41571-022-00606-4. Epub 2022 Feb 25.

本文引用的文献

1
Resistance to Avapritinib in PDGFRA-Driven GIST Is Caused by Secondary Mutations in the PDGFRA Kinase Domain.继发于 PDGFRA 激酶结构域的突变导致 PDGFRA 驱动的 GIST 对阿伐普利尼耐药。
Cancer Discov. 2021 Jan;11(1):108-125. doi: 10.1158/2159-8290.CD-20-0487. Epub 2020 Sep 24.
2
Switch Control Inhibition of KIT and PDGFRA in Patients With Advanced Gastrointestinal Stromal Tumor: A Phase I Study of Ripretinib.瑞普替尼治疗晚期胃肠间质瘤患者的 KIT 和 PDGFRA 开关控制抑制：一项Ⅰ期研究。
J Clin Oncol. 2020 Oct 1;38(28):3294-3303. doi: 10.1200/JCO.20.00522. Epub 2020 Aug 17.
3
Avapritinib in advanced PDGFRA D842V-mutant gastrointestinal stromal tumour (NAVIGATOR): a multicentre, open-label, phase 1 trial.阿伐普利尼治疗晚期 PDGFRA D842V 突变胃肠间质瘤（NAVIGATOR）：一项多中心、开放标签、1 期临床试验。
Lancet Oncol. 2020 Jul;21(7):935-946. doi: 10.1016/S1470-2045(20)30269-2.
4
Ripretinib: First Approval.瑞普替尼：首次获批。
Drugs. 2020 Jul;80(11):1133-1138. doi: 10.1007/s40265-020-01348-2.
5
Ripretinib in patients with advanced gastrointestinal stromal tumours (INVICTUS): a double-blind, randomised, placebo-controlled, phase 3 trial.瑞派替尼治疗晚期胃肠道间质瘤患者（INVICTUS）：一项双盲、随机、安慰剂对照、III 期临床试验。
Lancet Oncol. 2020 Jul;21(7):923-934. doi: 10.1016/S1470-2045(20)30168-6. Epub 2020 Jun 5.
6
Avapritinib: First Approval.阿伐普利替尼：首次获批
Drugs. 2020 Mar;80(4):433-439. doi: 10.1007/s40265-020-01275-2.
7
Avapritinib Approved for GIST Subgroup.阿伐替尼获批用于胃肠道间质瘤亚组。
Cancer Discov. 2020 Mar;10(3):334. doi: 10.1158/2159-8290.CD-NB2020-002. Epub 2020 Jan 23.
8
Intrigue: Phase III study of ripretinib versus sunitinib in advanced gastrointestinal stromal tumor after imatinib.瑞派替尼对比舒尼替尼用于伊马替尼治疗后进展的晚期胃肠间质瘤的 III 期研究。
Future Oncol. 2020 Jan;16(1):4251-4264. doi: 10.2217/fon-2019-0633. Epub 2019 Nov 22.
9
Comparison of effects of midostaurin, crenolanib, quizartinib, gilteritinib, sorafenib and BLU-285 on oncogenic mutants of KIT, CBL and FLT3 in haematological malignancies.比较米哚妥林、克立替尼、quizartinib、吉特替尼、索拉非尼和 BLU-285 对血液系统恶性肿瘤中 KIT、CBL 和 FLT3 致癌突变体的影响。
Br J Haematol. 2019 Nov;187(4):488-501. doi: 10.1111/bjh.16092. Epub 2019 Jul 15.
10
ATP-Competitive Inhibitors Midostaurin and Avapritinib Have Distinct Resistance Profiles in Exon 17-Mutant KIT.在携带外显子 17 突变的 KIT 中，ATP 竞争性抑制剂米哚妥林和艾伏尼布具有不同的耐药谱。
Cancer Res. 2019 Aug 15;79(16):4283-4292. doi: 10.1158/0008-5472.CAN-18-3139. Epub 2019 Jul 3.

Inhibition of KIT Tyrosine Kinase Activity: Two Decades After the First Approval.

作者信息

Klug Lillian R, Corless Christopher L, Heinrich Michael C

机构信息

Oregon Health & Science University, Knight Cancer Institute, Portland, OR.

Division of Hematology and Medical Oncology, Oregon Health & Science University, Portland, OR.

出版信息

J Clin Oncol. 2021 May 20;39(15):1674-1686. doi: 10.1200/JCO.20.03245. Epub 2021 Apr 2.

DOI:10.1200/JCO.20.03245
PMID:33797935
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC8274803/
Abstract
摘要